Tourmaline Bio, Inc. (TRML)
Fuera de horario:
Tourmaline Bio, Inc.
27 West 24th Street
Suite 702
New York, NY 10010
United States
646-481-9832
https://www.tourmalinebio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 44
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Sandeep C. Kulkarni M.D. | Co-Founder, CEO & Director | 753.02k | N/D | 1982 |
| Ms. Dora Rau | Senior Vice President & Head of Quality | N/D | N/D | N/D |
| Mr. Gerhard Hagn Pharm.D. | Senior VP and Head of Commercial & Business Development | N/D | N/D | N/D |
| Dr. Emil M. deGoma M.D. | Senior Vice President of Medical Research | N/D | N/D | N/D |
| Dr. Kristine Erickson O.D., Ph.D. | VP & TA Head of Ophthalmology, Medical Research | N/D | N/D | N/D |
| Dr. John Walsh M.D. | Vice President & Head of Medical Affairs | N/D | N/D | N/D |
| Ms. Famina Hemani Pharm.D. | VP & Head of Pharmacovigilance | N/D | N/D | N/D |
Descripción
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
Gestión corporativa
La calificación ISS Governance QuickScore de Tourmaline Bio, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
